The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome
- 1 September 2013
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 230 (1) , 6-11
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin TherapyNew England Journal of Medicine, 2011
- Cholesteryl Ester Transfer Protein Inhibition in Cardiovascular Risk Management: Ongoing Trials will End the ConfusionCardiovascular Therapeutics, 2010
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- Beyond High-Density Lipoprotein Cholesterol LevelsJACC, 2008
- Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deathsThe Lancet, 2007
- High-Density Lipoprotein as a Therapeutic TargetJAMA, 2007
- CETP inhibition in cardiovascular risk management: a critical appraisalEuropean Journal of Clinical Investigation, 2007
- Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and AtherosclerosisPharmacological Reviews, 2006